AbbottABT
ABT
About: Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Employees: 114,000
0
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 8 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
182% more first-time investments, than exits
New positions opened: 293 | Existing positions closed: 104
25% more call options, than puts
Call options by funds: $1.25B | Put options by funds: $999M
14% more funds holding in top 10
Funds holding in top 10: 63 [Q3] → 72 (+9) [Q4]
4% more funds holding
Funds holding: 2,853 [Q3] → 2,977 (+124) [Q4]
1.87% more ownership
Funds ownership: 75.95% [Q3] → 77.82% (+1.87%) [Q4]
3% more capital invested
Capital invested by funds: $151B [Q3] → $155B (+$4.61B) [Q4]
4% less repeat investments, than reductions
Existing positions increased: 1,106 | Existing positions reduced: 1,149
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$135
6%
upside
Avg. target
$147
16%
upside
High target
$160
26%
upside
8 analyst ratings
8 positive
100%
0 neutral
0%
0 negative
0%
B of A Securities Travis Steed 20% 1-year accuracy 1 / 5 met price target | 18%upside $150 | Buy Maintained | 10 Mar 2025 |
Citigroup Joanne Wuensch 44% 1-year accuracy 23 / 52 met price target | 26%upside $160 | Buy Maintained | 4 Mar 2025 |
Goldman Sachs David Roman 30% 1-year accuracy 6 / 20 met price target | 21%upside $154 | Buy Maintained | 4 Mar 2025 |
Barclays Matt Miksic 63% 1-year accuracy 26 / 41 met price target | 24%upside $158 | Overweight Maintained | 27 Jan 2025 |
RBC Capital Shagun Singh 61% 1-year accuracy 41 / 67 met price target | 6%upside $135 | Outperform Reiterated | 23 Jan 2025 |
Financial journalist opinion
Based on 18 articles about ABT published over the past 30 days
Positive
Zacks Investment Research
8 hours ago
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Positive
Zacks Investment Research
8 hours ago
Watch These 5 AI-Powered Healthcare Bigwigs for Portfolio Gains
Five AI-powered stocks have strong revenues and earnings growth potentials for 2025. These are: MDT, LLY, BSX, NVS, ABT.
Neutral
PRNewsWire
9 hours ago
Abbott Initiates New Intravascular Lithotripsy Clinical Trial to Improve Outcomes in Patients with Coronary Artery Disease
Coronary Artery Disease (CAD) is the most common heart disease and most frequent cause of death in the U.S., with over 20 million adults affected by this condition Abbott's investigational Coronary Intravascular Lithotripsy (IVL) System offers a new potential treatment by using sound pressure waves to treat arterial calcium blockages Abbott offers a comprehensive vascular portfolio of technologies designed to assess, treat and manage calcium buildup in coronary arteries ABBOTT PARK, Ill., March 24, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for its Coronary Intravascular Lithotripsy (IVL) System to evaluate the treatment of severe calcification in coronary arteries prior to stenting.
Positive
Seeking Alpha
3 days ago
2025 Dividend Kings: Strong Run Continues
The Dividend Kings are outperforming the S&P 500 in 2025 by 4.57%. Top performers include National Fuel & Gas (+30.21%), Consolidated Edison (+22.66%), and AbbVie (+20.40%). Promising Dividend Kings identified in February showed relative outperformance, averaging -0.38% vs. -1.58% for all Kings and -3.34% for SPY.
Neutral
Zacks Investment Research
6 days ago
Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Neutral
Zacks Investment Research
1 week ago
Abbott Laboratories Gains 12.7% in a Year: What's Driving the Stock?
ABT's shares rise on the back of its diversified business portfolio. However, the unfavorable macroeconomic scenario is concerning.
Positive
Seeking Alpha
1 week ago
Abbott Stock Could Be On The Verge Of A Breakout - Here's What Smart Money Sees
Abbott Laboratories is undervalued by the market, despite its strong fundamentals and strategic moves in high-growth areas like diabetes care and weight-loss treatments. The company boasts a high net income margin of 31.95% and generates over $8.5 billion in cash from operations, providing significant flexibility. Abbott's FreeStyle Libre system and new Protality brand highlight its long-term growth potential in diabetes care and weight-loss treatment markets.
Neutral
Zacks Investment Research
1 week ago
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
Positive
The Motley Fool
2 weeks ago
2 Dependable Dividend Stocks That Can Pay You for Life
What makes an outstanding dividend stock? High yields can seem attractive to income seekers, but unless a company has a steady, reliable business, payout cuts are a real possibility no matter how juicy its dividend yield.
Positive
FXEmpire
2 weeks ago
Strong Earnings Lift Abbott Laboratories Shares
Health care company Abbott Laboratories (ABT) increases sales, earnings around the globe.
Charts implemented using Lightweight Charts™